Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased organizational disciplineStrong revenue outlook, procedure growth, expanding margins, and path to profitabilityLonger-term growth drivers include market expansion and expanded application into prostate cancer NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient ...

SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. “In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter,” said Larry Wood, Chief Executive Offic ...

Core Viewpoint - Procept Biorobotics Corp. (NASDAQ:PRCT) is identified as a promising mid-cap healthcare stock with significant upside potential, supported by bullish analyst ratings and growth prospects [1][3]. Group 1: Analyst Ratings and Price Targets - UBS analyst Danielle Antalffy initiated coverage with a Buy rating and a target price of $62, indicating an upside potential of over 93% from current levels [1][2]. - As of December 19, 80% of 10 analyst ratings for the stock were Buy calls, with a 1-year average price target of $51.75, suggesting over 61% upside potential [3]. Group 2: Company Overview and Growth Prospects - Procept Biorobotics Corp. specializes in surgical robotics, focusing on robotic treatments for male urological health, particularly through its flagship Aquablation® therapy [4]. - The company aims to increase the utilization of its current installed base and expand into new markets, with expectations of turning profitable by 2027 due to revenue growth, improved gross margins, and operational efficiencies [2].

Core Insights - PROCEPT BioRobotics announced the appointment of Larry L. Wood as president and CEO effective September 2, 2025, succeeding Dr. Reza Zadno who will retire on September 1, 2025 [1][3] - Dr. Zadno has led the company through significant growth, including the adoption of Aquablation® therapy for BPH treatment and a successful public offering in 2021 [2][3] - The company pre-announced second quarter 2025 revenue of approximately $79.2 million, representing an annual growth of 48% [5][4] Leadership Transition - Larry L. Wood brings over 40 years of experience in the medical technology industry, previously serving at Edwards Lifesciences and Baxter Healthcare [4][3] - Wood has been a member of PROCEPT BioRobotics' board of directors since 2024 and is recognized for his leadership in the medical device sector [4][3] - The board expressed confidence in Wood's ability to lead the company through its next growth phase, emphasizing his experience in clinically demanding medical device categories [4][3] Company Performance - Under Dr. Zadno's leadership, the number of global Aquablation procedures increased from a few hundred to nearly 100,000, and the company raised over $600 million in capital [2][3] - The company aims to revolutionize BPH treatment globally by delivering advanced robotic solutions that positively impact patient care [5][6] - PROCEPT BioRobotics has developed a significant body of clinical evidence supporting the benefits of Aquablation therapy, with over 150 peer-reviewed publications [6]